ArticleTrials2022

HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia-rationale, study design and protocol.

Victor Chong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.